13F-HR filed by Versant Venture Management, LLC
Versant Venture Management, LLC filed this 13F-HR for the quarter ended 2019-12-31, filed 2020-01-21, with 7 holding rows worth $331,845,613.
- Accession
- 0001104659-20-005491
- Filer
- CIK 1560009
- Filed
- 2020-01-21
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2019
A holdings report, 7 entries on the cover page, a total value of $331,845,613 stated on the cover page (in dollars after the unit check, H1), rows summing to $331,845,612 with VALUE read as dollars, detected, 13F file number 028-16849. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 4,205,615 | $256,142,982 | dollars, detected | |
| VERACYTE INC COM | 92337F107 | Stock | 1,205,407 | $33,654,963 | dollars, detected | |
| GRITSTONE BIO INC | 39868T105 | COM | 3,102,929 | $27,833,273 | dollars, detected | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 2,215,384 | $8,750,767 | dollars, detected | |
| SECOND SIGHT MED PRODS INC | 81362J100 | COM | 4,492,975 | $3,336,034 | dollars, detected | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 543,753 | $1,065,755 | dollars, detected | |
| CLOVIS ONCOLOGY INC | 189464100 | COM | 101,855 | $1,061,838 | dollars, detected |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-20-005491 | this filing | 2020-01-21 | acceptance time not in the bulk data set |